Literature DB >> 26267233

Adult-onset congenital thrombotic thrombocytopenic purpura caused by a novel compound heterozygous mutation of the ADAMTS13 gene.

Johannes G Krabbe1,2, Evelien W M Kemna3, Annuska L M Strunk4, Pieter A Jobse5, P A Kramer4, L D Dikkeschei4, L P W J van den Heuvel6, Rob Fijnheer7, Leo F Verdonck5.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease, characterized by microangiopathic hemolytic anaemia and thrombocytopenia, resulting in neurologic and/or renal abnormalities. We report a 49-year-old patient with a history of thrombotic events, renal failure, and thrombocytopenia. Blood analysis demonstrated no ADAMTS13 activity in the absence of antibodies against ADAMTS13. The complete ADAMTS13 gene was sequenced, and two mutations were identified: one mutation on exon 24 (Arg1060Asp), which had previously been described, and a mutation on exon 27 (Met1260IlefsX34), which has not been reported. For these mutations, compound heterozygosity appears to be necessary to cause TTP, as family members of the patient display only one of the mutations and all displayed normal ADAMTS13 activity.

Entities:  

Keywords:  ADAMTS13; Compound heterozygosity; Congenital; Thrombotic thrombocytopenic purpura

Mesh:

Substances:

Year:  2015        PMID: 26267233     DOI: 10.1007/s12185-015-1849-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

1.  Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Authors:  Z Tao; K Anthony; Y Peng; H Choi; L Nolasco; L Rice; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2006-06-22       Impact factor: 5.824

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay.

Authors:  Koichi Kokame; Yuko Nobe; Yoshihiro Kokubo; Akira Okayama; Toshiyuki Miyata
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

4.  Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.

Authors:  M Furlan; R Robles; B Morselli; P Sandoz; B Lämmle
Journal:  Thromb Haemost       Date:  1999-01       Impact factor: 5.249

5.  Binding of ADAMTS13 to von Willebrand factor.

Authors:  Elaine M Majerus; Patricia J Anderson; J Evan Sadler
Journal:  J Biol Chem       Date:  2005-04-11       Impact factor: 5.157

Review 6.  ADAMTS13 activity and genetic mutations in Japan.

Authors:  T Miyata; K Kokame; M Matsumoto; Y Fujimura
Journal:  Hamostaseologie       Date:  2013-05-29       Impact factor: 1.778

Review 7.  Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.

Authors:  Chantal Loirat; Jean-Pierre Girma; Céline Desconclois; Paul Coppo; Agnès Veyradier
Journal:  Pediatr Nephrol       Date:  2008-06-24       Impact factor: 3.714

8.  Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura.

Authors:  Toshihiro Uchida; Hideo Wada; Minoru Mizutani; Miho Iwashita; Hiroaki Ishihara; Toshiro Shibano; Misako Suzuki; Yumiko Matsubara; Kenji Soejima; Masanori Matsumoto; Yoshihiro Fujimura; Yasuo Ikeda; Mitsuru Murata
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the ADAMTS13 gene.

Authors:  Cecilie Utke Rank; Johanna Kremer Hovinga; Magnus Mansouri Taleghani; Bernhard Lämmle; Jens Peter Gøtze; Ove Juul Nielsen
Journal:  Eur J Haematol       Date:  2013-12-10       Impact factor: 2.997

Review 10.  How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.

Authors:  Marie Scully; Tim Goodship
Journal:  Br J Haematol       Date:  2014-01-06       Impact factor: 6.998

View more
  1 in total

Review 1.  ADAMTS13: more than a regulator of thrombosis.

Authors:  Yun Feng; Xueyin Li; Juan Xiao; Wei Li; Jing Liu; Xue Zeng; Xi Chen; Suhua Chen
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.